ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today shared positive in vitro findings showing that an investigational integrase strand transfer inhibitor (INSTI), VH4524184 (VH184), retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Additional analysis presented of a phase I study showed pharmacokinetic (PK) and safety data supported further development of VH184.¹ The findings are being presented at the 25^th International AIDS Conference (AIDS 2024) being held in Munich, Germany, from 22 – 26 July 2024.

Additional information to the following link: ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor | GSK